Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.85 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.80 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27966667 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL380682 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20348156 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29509989 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL23014594 | 0.99 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19359081 | 0.99 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29651526 | 0.99 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL21410668 | 0.99 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29651531 | 0.99 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL15798371 | 0.97 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024138205-A2 | PRODUCTION OF CANNABINOIDS AND ENGINEERED CELLS THEREFOR | CELLIBRE, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20180187169-A1 | THIOLASE VARIANTS AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-05 | — | — | US | claimed |
| WO-2018035270-A1 | THIOLASE VARIANTS AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-22 | — | — | WO | claimed |
| EP-2791347-A2 | METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE | Invista Technologies S.à.r.l. (CH) | 2014-10-22 | — | — | EP | claimed |
| WO-2013090837-A2 | METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2013-06-20 | — | — | WO | claimed |
| WO-2012135731-A2 | ALCOHOL PRODUCTION FROM RECOMBINANT MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-04 | — | — | WO | claimed |
| US-8049065-B2 | Transgenic systems for the manufacture of poly(2-hydroxy-butyrate-co-3-hydroxyhexanoate) | METABOLIX, INC. (US) | 2011-11-01 | — | — | US | claimed |
| US-20100311131-A1 | TRANSGENIC SYSTEMS FOR THE MANUFACTURE OF POLY(2-HYDROXY-BUTYRATE-CO-3-HYDROXYHEXANOATE) | METABOLIX, INC. | 2010-12-09 | — | — | US | claimed |
| EP-2088198-A2 | Transgenic systems for the manufacture of poly(3-hydroxy-butyrate-CO-3-hydroxyhexanoate) | Metabolix, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1208208-B1 | TRANSGENIC SYSTEMS FOR THE MANUFACTURE OF POLY(3-HYDROXY -BUTYRATE -CO -3- HYDROXYHEXANOATE) | METABOLIX INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7455999-B2 | Transgenic systems for the manufacture of poly (3-hydroxy-butyrate-co-3-hydroxyhexanoate) | METABOLIX, INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1700908-A2 | Transgenic microbial polyhydroxyalkanoate producers | Metabolix, Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| EP-3346011-B1 | HOST CELLS FOR PREPARING ADIPATE (ESTER OR THIOESTER) | GENOMATICA INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | AGAIN BIO APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250361532-A1 | BIDIRECTIONAL MULTI-ENZYMATIC SCAFFOLDS FOR BIOSYNTHESIZING CANNABINOIDS | KHONA SCIENT HOLDINGS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4638753-A2 | PRODUCTION OF CANNABINOIDS AND ENGINEERED CELLS THEREFOR | Cellibre, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-1105499-A1 | TRANSGENIC MICROBIAL POLYHYDROXYALKANOATE PRODUCERS | METABOLIX, INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000043523-A2 | TRANSGENIC SYSTEMS FOR THE MANUFACTURE OF POLY(3-HYDROXY -BUTYRATE -CO -3- HYDROXYHEXANOATE) | METABOLIX, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000040730-A1 | POLYHYDROXYALKANOATE BIOSYNTHESIS ASSOCIATED PROTEINS AND CODING REGION IN $i(BACILLUS MEGATERIUM) | UNIVERSITY OF MASSACHUSETTS (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000011188-A1 | TRANSGENIC MICROBIAL POLYHYDROXYALKANOATE PRODUCERS | METABOLIX, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | ADH5, ADH1C, ADH1A | NAA50 426/4885CHAT 1999/4885EP300 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.